Unknown PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT00966810

Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion

Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion and Preemptive Donor Lymphocyte Infusion.

Sponsor: Miltenyi Biomedicine GmbH

Conditions Philadelphia Chromosome-positive Chronic Myelocytic Leukemia

Updated 6 times since 2017 Last updated: Aug 26, 2009 Started: Dec 31, 1999 Primary completion: Jan 31, 2010 Completion: Jan 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Philadelphia Chromosome-positive Chronic Myelocytic Leukemia and is currently ongoing. Miltenyi Biomedicine GmbH leads this study, which shows 6 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3
Aug 2020 — Jan 2021 [monthly]

Unknown Status PHASE2_PHASE3
Feb 2020 — Aug 2020 [monthly]

Unknown Status PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2020 [monthly]

Unknown Status PHASE2_PHASE3

First recorded

Dec 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Miltenyi Biomedicine GmbH
Rambam Health Care Campus

Data source: Rambam Health Care Campus

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Haifa, Israel